IMIG

IMIG stands for the International Mesothelioma Interest Group, a global professional organization of physicians, surgeons, pathologists, and scientists dedicated to research, diagnosis, and treatment of mesothelioma. Founded in 1991, IMIG holds a major international conference every two years where leading experts share the latest findings on mesothelioma biology, staging, surgery, chemotherapy, immunotherapy, and patient care. The group has also developed consensus guidelines that shape how mesothelioma is staged, diagnosed pathologically, and treated worldwide.

Origin

IMIG was established in 1991 by a small group of clinicians and researchers who recognized that mesothelioma, though rare, required dedicated, coordinated international study because no single institution saw enough cases to advance the field alone. The first IMIG conference was held in Paris in 1991, and the group has met biennially ever since in cities including Perth, Boston, Brussels, Cape Town, Kyoto, and Lille.

Significance in Asbestos Context

For patients, IMIG matters because the staging systems, pathology criteria, and treatment standards their doctors use to manage mesothelioma often trace back to IMIG consensus statements. The IMIG/IASLC staging system, for example, defines how tumor extent is described in medical records and influences whether a patient is offered surgery, chemotherapy, immunotherapy, or clinical trial enrollment. In a legal claim, expert witnesses frequently cite IMIG guidelines to establish that a diagnosis was made and a treatment plan recommended according to internationally accepted standards, which strengthens the credibility of both the medical record and the damages claim built on it.

Example Sentence

The oncologist explained that the staging in the pathology report followed the IMIG/IASLC system, which would determine whether surgery was an option.

Related Terms

Mesothelioma, TNM Staging, Pleural Mesothelioma, Pathology Report, IASLC, Helsinki Criteria

Notes

• Ask your treating physician whether your case has been reviewed against current IMIG staging and pathology guidelines, especially if a second opinion is being considered.
• Patients with mesothelioma should ask about clinical trials presented at recent IMIG conferences. Many novel therapies enter trials shortly after being featured there.
• Keep copies of all pathology reports and staging documentation; references to IMIG criteria in these records can support both medical decisions and legal claims.
• If you are seeking a specialist, mesothelioma programs whose physicians actively participate in IMIG are typically among the most experienced centers worldwide.